Saturday, 31 October 2026European Markets

SQLI Stock Slides 9% On Friday, Underperforms Market

Loading stream...

(vianews) - shares of sqli (cac 40: sqi.pa) fell 9.18% to 38.60 € at 16:09 est on friday, after three sequential sessions in a row of losses. cac 40 is falling 0.95% to 7,119.82 €, following the last session's upward trend. this seems, up to now, a somewhat bearish trend exchanging session today.

about sqli

sqli sa engages in digital experience and unified commerce businesses worldwide. it offers digital transformation services, including business and it consulting, implementation, and maintenance solutions to support large companies and local authorities. the company also provides technological platforms development; big data consulting and solutions; mobile solutions and connected objects; digital and social marketing; connected commerce; data marketing; and ux and new practices solutions. in addition, it offers digital experience platforms, marketing and experience design, digital workplace, strategy and digital transformation consulting, and marketing and technological performance solutions. the company was incorporated in 1990 and is headquartered in levallois-perret, france. as of february 1, 2022, sqli sa was taken private.

earnings per share

as for profitability, sqli has a trailing twelve months eps of 0.04 €.

pe ratio

sqli has a trailing twelve months price to earnings ratio of 1015.79. meaning, the purchaser of the share is investing 1015.79 € for every euro of annual earnings.

volatility

sqli's last week, last month's, and last quarter's current intraday variation average was a negative 0.47%, a negative 0.31%, and a positive 1.40%.

sqli's highest amplitude of average volatility was 0.47% (last week), 0.74% (last month), and 1.40% (last quarter).

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, sqli's stock is considered to be overbought (>=80).

more news about sqli (sqi.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com